BioCryst Pharmaceuticals, Inc.
NASDAQ: BCRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Charles K. Gayer
- Employees
- 580
- Headquarters
- Durham, United States
- IPO year
- 1994
- Market cap
- $2.1B
- Website
- https://www.biocryst.com
Loading BCRX…
Loading profile data…Frequently asked questions about BCRX
What does BioCryst Pharmaceuticals, Inc. (BCRX) do?
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment o...
Where does BCRX trade?
BioCryst Pharmaceuticals, Inc. (BCRX) trades on the NASDAQ Global Select.
What sector is BCRX in?
BioCryst Pharmaceuticals, Inc. (BCRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioCryst Pharmaceuticals, Inc.?
Charles K. Gayer is the chief executive officer of BioCryst Pharmaceuticals, Inc. (BCRX).
Where is BioCryst Pharmaceuticals, Inc. headquartered?
BioCryst Pharmaceuticals, Inc. is headquartered in United States.
Does BCRX pay a dividend?
BioCryst Pharmaceuticals, Inc. (BCRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCRX go public?
BioCryst Pharmaceuticals, Inc. (BCRX) completed its initial public offering in 1994.